Engage Therapeutics sponsors Kurt Eichenwald’s Miami appearance to discuss “A Mind Unravled,” a chronicle of his life with epilepsy.

Engage Therapeutics Presents Data from Part 1, Open-label Run-in of StATES Phase 2b Study of Staccato® Alprazolam at 2019 American Academy of Neurology Annual Meeting
May 6, 2019
Interview with Engage Therapeutics’ founder Greg Mayes appears in Epilepsy Foundation’s June 2019 Research Quarterly
July 1, 2019

MIAMI, July 01, 2019 (GLOBE NEWSWIRE) — New York Times bestselling author Kurt Eichenwald will be at the Mayfair Hotel and Spa in Coconut Grove on Thursday, July 11, at 7 p.m. to discuss his 2018 memoir, “A Mind Unraveled,” in which he details his personal battle with epilepsy. The free event is in the Mayfair’s Crystal Ballroom at 3000 Florida Ave.

The event is sponsored by Engage Therapeutics, a company founded by a biopharmaceutical executive whose son has epilepsy, in collaboration with Nicklaus Children’s HospitalFirst Choice NeurologyEpilepsy FloridaAdvanced Pharma-Miami, and the University of Miami Health System. Engage Therapeutics is developing Staccato® alprazolam, a hand-held inhaler that delivers alprazolam with a single breath and is designed to give people with epilepsy and their caregivers a way to stop an ongoing seizure.

In addition to Mr. Eichenwald, several local epilepsy experts will be at the event, including Ian Miller, MD, Director, Epilepsy and Neurophysiology Program at Nicklaus Hospital and First Choice Neurology; Patricia Dean, ARNP, MSN, Clinical Coordinator of the Comprehensive Epilepsy Center at Nicklaus Children’s Hospital and Chair of Epilepsy Florida; Kimberly Cruz, MD, Medical Director and Principal Investigator at Advanced Pharma – Miami; and Kamil Detyniecki, MD, Associate Professor of Clinical Neurology at University of Miami and University of Miami Health System.

An award-winning journalist, Mr. Eichenwald has authored five books. His second book, “The Informant,” was made into a movie starring Matt Damon and directed by Steven Soderbergh. He is a senior writer at Newsweek and a contributing editor at Vanity Fair, and he spent two decades as a senior writer at The New York Times, where he was a two-time finalist for the Pulitzer Prize. Mr. Eichenwald also is a two-time winner of the George Polk Award, as well as the winner of the Payne Award for Ethics in Journalism and an Emmy Award nominee.

He also has earned wide acclaim for his memoir, the story of his battle to pursue his dreams despite his incapacitating epilepsy. As a college freshman, Mr. Eichenwald awoke one night on the floor of his dorm room, confused and in pain. In the aftermath of that critical moment, his once, care-free life became consumed by confrontations with medical incompetence, discrimination that almost cost him his education and employment, physical abuse, and dark moments when he contemplated suicide.

“A Mind Unraveled is an inspiring story about perseverance and fortitude in overcoming the paralyzing fear of seizures and extreme helplessness people with epilepsy live with every day,” said Gregory T. Mayes, Founder and CEO of Engage Therapeutics. Mr. Mayes, whose career in the biopharmaceutical industry has spanned more than 20 years, became involved in the epilepsy community following his teenage son’s epilepsy diagnosis in 2014. Leveraging his drug development experience and deep roots in the pharmaceutical industry, he founded Engage Therapeutics in 2017 to develop what could be the U.S.’s first seizure rescue inhaler.

Engage Therapeutics is sponsoring the multi-center StATES Study (Staccato Alprazolam TerminateEpileptic Seizures – NCT03478982), a phase 2b trial designed to evaluate the safety, efficacy and usability of Staccato alprazolam in patients with epilepsy who have a predictable seizure pattern. The StATES study is being conducted at approximately 50 trial sites in the United States, Australia, Canada and Jamaica. Please visit www.epilepsyhealthstudy.com for more information about the StATES study and www.engagetherapeutics.com/study-locations/ for a list of study locations.